Cargando…
Genotype–phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France
OBJECTIVE: To compare the natural history of familial transthyretin amyloid polyneuropathies (FAP) due to the Val30Met, Ser77Tyr, and Ile107Val mutations in France with the classical Portuguese Val30Met FAP. METHODS: We compared 84 French patients with a control group of 110 Portuguese patients carr...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4738459/ https://www.ncbi.nlm.nih.gov/pubmed/26369527 http://dx.doi.org/10.1002/ana.24519 |
_version_ | 1782413616001056768 |
---|---|
author | Mariani, Louise‐Laure Lozeron, Pierre Théaudin, Marie Mincheva, Zoia Signate, Aissatou Ducot, Beatrice Algalarrondo, Vincent Denier, Christian Adam, Clovis Nicolas, Guillaume Samuel, Didier Slama, Michel S. Lacroix, Catherine Misrahi, Micheline Adams, David |
author_facet | Mariani, Louise‐Laure Lozeron, Pierre Théaudin, Marie Mincheva, Zoia Signate, Aissatou Ducot, Beatrice Algalarrondo, Vincent Denier, Christian Adam, Clovis Nicolas, Guillaume Samuel, Didier Slama, Michel S. Lacroix, Catherine Misrahi, Micheline Adams, David |
author_sort | Mariani, Louise‐Laure |
collection | PubMed |
description | OBJECTIVE: To compare the natural history of familial transthyretin amyloid polyneuropathies (FAP) due to the Val30Met, Ser77Tyr, and Ile107Val mutations in France with the classical Portuguese Val30Met FAP. METHODS: We compared 84 French patients with a control group of 110 Portuguese patients carrying the Val30Met mutation also living in France, all referred to and followed at the French National FAP Reference Center from 1988 to 2010. Clinical examination, functional and walking disability scores, nerve conduction studies, and muscle biopsies are reported. We also conducted a comprehensive literature review to further determine the range of phenotypic expression. RESULTS: By comparison with Portuguese Val30Met FAP, French Ile107Val, Ser77Tyr, and LateVal30Met FAP showed more rapid and severe disease progression; onset of gait disorders was 3 times more rapid (p < 0.0001) and the rate of modified Norris test decline was up to 40 times faster in Ile107Val patients (p < 0.0001). Median survival was much shorter in Ile107Val and in Val30Met mutation with late onset (>50 years; LateMet30) FAP (p = 0.0005). Other distinctive features relative to the Portuguese patients included atypical clinical presentations, demyelination on nerve conduction studies (p = 0.0005), and difficult identification of amyloid deposits in nerve and muscle biopsies. INTERPRETATION: Ile107Val and LateMet30 mutations are associated with the most debilitating and severe FAP ever described, with rapid onset of tetraparesis and shorter median survival. It could be explained by frequent large‐fiber involvement and associated demyelination and more severe axonal loss. These findings have major implications for genetic counseling and patient management as new therapeutic options are being assessed in clinical trials (TTR gene silencing). Ann Neurol 2015;78:901–916 |
format | Online Article Text |
id | pubmed-4738459 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-47384592016-02-12 Genotype–phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France Mariani, Louise‐Laure Lozeron, Pierre Théaudin, Marie Mincheva, Zoia Signate, Aissatou Ducot, Beatrice Algalarrondo, Vincent Denier, Christian Adam, Clovis Nicolas, Guillaume Samuel, Didier Slama, Michel S. Lacroix, Catherine Misrahi, Micheline Adams, David Ann Neurol Research Articles OBJECTIVE: To compare the natural history of familial transthyretin amyloid polyneuropathies (FAP) due to the Val30Met, Ser77Tyr, and Ile107Val mutations in France with the classical Portuguese Val30Met FAP. METHODS: We compared 84 French patients with a control group of 110 Portuguese patients carrying the Val30Met mutation also living in France, all referred to and followed at the French National FAP Reference Center from 1988 to 2010. Clinical examination, functional and walking disability scores, nerve conduction studies, and muscle biopsies are reported. We also conducted a comprehensive literature review to further determine the range of phenotypic expression. RESULTS: By comparison with Portuguese Val30Met FAP, French Ile107Val, Ser77Tyr, and LateVal30Met FAP showed more rapid and severe disease progression; onset of gait disorders was 3 times more rapid (p < 0.0001) and the rate of modified Norris test decline was up to 40 times faster in Ile107Val patients (p < 0.0001). Median survival was much shorter in Ile107Val and in Val30Met mutation with late onset (>50 years; LateMet30) FAP (p = 0.0005). Other distinctive features relative to the Portuguese patients included atypical clinical presentations, demyelination on nerve conduction studies (p = 0.0005), and difficult identification of amyloid deposits in nerve and muscle biopsies. INTERPRETATION: Ile107Val and LateMet30 mutations are associated with the most debilitating and severe FAP ever described, with rapid onset of tetraparesis and shorter median survival. It could be explained by frequent large‐fiber involvement and associated demyelination and more severe axonal loss. These findings have major implications for genetic counseling and patient management as new therapeutic options are being assessed in clinical trials (TTR gene silencing). Ann Neurol 2015;78:901–916 John Wiley and Sons Inc. 2015-10-07 2015-12 /pmc/articles/PMC4738459/ /pubmed/26369527 http://dx.doi.org/10.1002/ana.24519 Text en © 2015 The Authors. Annals of Neurology published by Wiley Periodicals, Inc. on behalf of American Neurological Association This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Research Articles Mariani, Louise‐Laure Lozeron, Pierre Théaudin, Marie Mincheva, Zoia Signate, Aissatou Ducot, Beatrice Algalarrondo, Vincent Denier, Christian Adam, Clovis Nicolas, Guillaume Samuel, Didier Slama, Michel S. Lacroix, Catherine Misrahi, Micheline Adams, David Genotype–phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France |
title | Genotype–phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France |
title_full | Genotype–phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France |
title_fullStr | Genotype–phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France |
title_full_unstemmed | Genotype–phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France |
title_short | Genotype–phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France |
title_sort | genotype–phenotype correlation and course of transthyretin familial amyloid polyneuropathies in france |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4738459/ https://www.ncbi.nlm.nih.gov/pubmed/26369527 http://dx.doi.org/10.1002/ana.24519 |
work_keys_str_mv | AT marianilouiselaure genotypephenotypecorrelationandcourseoftransthyretinfamilialamyloidpolyneuropathiesinfrance AT lozeronpierre genotypephenotypecorrelationandcourseoftransthyretinfamilialamyloidpolyneuropathiesinfrance AT theaudinmarie genotypephenotypecorrelationandcourseoftransthyretinfamilialamyloidpolyneuropathiesinfrance AT minchevazoia genotypephenotypecorrelationandcourseoftransthyretinfamilialamyloidpolyneuropathiesinfrance AT signateaissatou genotypephenotypecorrelationandcourseoftransthyretinfamilialamyloidpolyneuropathiesinfrance AT ducotbeatrice genotypephenotypecorrelationandcourseoftransthyretinfamilialamyloidpolyneuropathiesinfrance AT algalarrondovincent genotypephenotypecorrelationandcourseoftransthyretinfamilialamyloidpolyneuropathiesinfrance AT denierchristian genotypephenotypecorrelationandcourseoftransthyretinfamilialamyloidpolyneuropathiesinfrance AT adamclovis genotypephenotypecorrelationandcourseoftransthyretinfamilialamyloidpolyneuropathiesinfrance AT nicolasguillaume genotypephenotypecorrelationandcourseoftransthyretinfamilialamyloidpolyneuropathiesinfrance AT samueldidier genotypephenotypecorrelationandcourseoftransthyretinfamilialamyloidpolyneuropathiesinfrance AT slamamichels genotypephenotypecorrelationandcourseoftransthyretinfamilialamyloidpolyneuropathiesinfrance AT lacroixcatherine genotypephenotypecorrelationandcourseoftransthyretinfamilialamyloidpolyneuropathiesinfrance AT misrahimicheline genotypephenotypecorrelationandcourseoftransthyretinfamilialamyloidpolyneuropathiesinfrance AT adamsdavid genotypephenotypecorrelationandcourseoftransthyretinfamilialamyloidpolyneuropathiesinfrance AT genotypephenotypecorrelationandcourseoftransthyretinfamilialamyloidpolyneuropathiesinfrance |